Stock A086460 CURABLE. INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Curable. Inc.

Equities

A086460

KR7086460003

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-06-06 EDT 		5-day change 1st Jan Change
3,025 KRW +7.65% Intraday chart for Curable. Inc. +15.90% -53.96%
2023 Curable. Inc. agreed to acquire 8.5% stake in Pharma Biotech Korea Co., Ltd from Pharma Biotech Korea for KRW 8.5 billion. CI
2023 Curable. Inc. announced that it has received KRW 5.0009986 billion in funding from GW Vitek CO.,LTD. CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Curable. Inc. agreed to acquire 8.5% stake in Pharma Biotech Korea Co., Ltd from Pharma Biotech Korea for KRW 8.5 billion.
CI
An unknown buyer agreed to acquire 16.82% of stake in SNP Genetics Inc. from Jo, Jin-hwan and others for KRW 3.7 billion.
CI
GW Vitek CO.,LTD. agreed to acquire a 40.7% stake in SNP Genetics Inc. from Hyoung-doo Shin and Myung-cheol Kim for KRW 9.4 billion.
CI
Tranche Update on SNP Genetics Inc.'s Equity Buyback Plan announced on November 2, 2020.
CI
SNP Genetics Inc.'s Equity Buyback announced on November 2, 2020, has expired with 110,000 shares, for KRW 104.72 million.
CI
SNP Genetics Inc. announces an Equity Buyback for 277,777 shares, for KRW 1,000 million.
CI
SNP Genetics Inc. authorizes a Buyback Plan.
CI
SNP Genetics Inc. cancelled the acquisition of an additional 0.99% stake in Enzychem Lifesciences Corporation from Capitalworks Investment Co.,Ltd.
CI
SNP Genetics Inc. acquired an additional 0.82% stake in Enzychem Lifesciences Corporation.
CI
SNP Genetics Inc. acquired an additional 0.02% stake in Enzychem Lifesciences Corporation.
CI
SNP Genetics Inc. agreed to acquire an additional 0.99% stake in Enzychem Lifesciences Corporation from Capitalworks Investment Co.,Ltd. for KRW 780 million.
CI
SNP Genetics Inc. acquired an additional 0.05% stake in Enzychem Lifesciences Corporation.
CI
SNP Genetics Inc. acquired an additional 0.025% stake in Enzychem Lifesciences Corporation.
CI
Cheol-Hoon Oh, Myoung-Ho Kim, Hyoung-Doo Shin, SNP Genetics Inc., Mi-Soon Kim, S&F Venture Capital Co., Ltd., Sang-Ho Jung and Nano SM Co., Ltd. acquired 3.4% stake in Enzychem Lifesciences Corporation from Capitalworks Investment Co.,Ltd. for KRW 1.7 billion.
CI
Tranche Update on SNP Genetics Inc.'s Equity Buyback Plan announced on November 15, 2013.
CI
SNP Genetics Inc.’s Equity Buyback announced on November 15, 2013 has expired with 75,000 shares for KRW 210 million.
CI
SNP Genetics Inc. authorizes a Buyback Plan.
CI
SNP Genetics Inc. announces an Equity Buyback for 141,700 shares.
CI
SNP Genetics Inc.'s Equity Buyback announced on October 9, 2013 has expired.
CI
SNP Genetics Inc. announces an Equity Buyback
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A086460 Stock
  4. News Curable. Inc.
  5. Highlights